At a glance
ClinicalIndex Comparison RecordN/ACompleted· 179 enrolled
Drug / intervention
Firazyrdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
FIRAZYR General Drug Use-Results Survey (Japan)
In Brief
An observational study evaluating Firazyr for Hereditary Angioedema (HAE). Completed, enrolled 179 participants across 18 sites.
Detailed Summary
The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema (HAE)
CountriesJapan
CollaboratorsTakeda
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedAug 2019
Primary CompletionJul 2024
TodayJul 2026
First PostedAug 15, 2019
Enrollment StartNov 20, 2018
Primary CompletionJul 29, 2024
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 6.9 years ago
Interventions
Firazyrdrug
Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.